PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,725,000 | -65.3% | 29,161 | -60.1% | 0.01% | -67.6% |
| Q1 2018 | $4,968,000 | +94.8% | 73,003 | +183.0% | 0.03% | +70.0% |
| Q4 2017 | $2,550,000 | -61.3% | 25,800 | -53.1% | 0.02% | -52.4% |
| Q3 2017 | $6,593,000 | -19.7% | 55,058 | -41.4% | 0.04% | -19.2% |
| Q2 2017 | $8,215,000 | +41.0% | 93,993 | -40.0% | 0.05% | +10.6% |
| Q1 2017 | $5,825,000 | +148.4% | 156,597 | +105.0% | 0.05% | +104.3% |
| Q4 2016 | $2,345,000 | +92.8% | 76,400 | +321.2% | 0.02% | +109.1% |
| Q3 2016 | $1,216,000 | -60.1% | 18,140 | -30.4% | 0.01% | -64.5% |
| Q2 2015 | $3,045,000 | +265.1% | 26,079 | +638.6% | 0.03% | +287.5% |
| Q1 2015 | $834,000 | -28.7% | 3,531 | -27.9% | 0.01% | -55.6% |
| Q3 2014 | $1,169,000 | +328.2% | 4,900 | +18.4% | 0.02% | +200.0% |
| Q2 2014 | $273,000 | -92.8% | 4,140 | -88.6% | 0.01% | -91.3% |
| Q1 2014 | $3,770,000 | +328.4% | 36,200 | +325.9% | 0.07% | +305.9% |
| Q4 2013 | $880,000 | – | 8,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |